NEWS DESK

EVMN Stock News, News Score & What It Could Mean

Evommune, Inc. Common Stock (EVMN) is currently showing a bearish headline tone with a mixed / range backdrop. The latest news flow is being framed here as context rather than prediction, so beginners can quickly see whether headlines are helping, hurting, or complicating the chart story. Earnings tone is currently mixed earnings tone.

HEADLINE TAKE: Higher-value headlines lean clearly negative, with stronger signals around downgrades, warnings, weak results, or other pressure points.
Change stock
Search another ticker to view its latest news page.
OPEN ON TRADINGVIEW ↗TRADE THIS STOCK
Full chart, indicators and drawing tools on TradingView. Move to Platforms when you are ready to act.
NEWS SCORE
33/100
Bearish
Bearish
Neutral
Bullish
Earnings Tone
55
Neutral based on actual EPS/revenue
Confidence
Medium
Headline depth
Last Price
$12.45
Trend Context
Mixed / range
Latest briefing

What's happening with EVMN

prnewswire.com7 Jul 2026

Evommune, Inc. (EVMN) Securities Fraud Investigation - Levi & Korsinsky

Evommune stock dropped approximately 38% after EVO756 missed its Phase 2b primary endpoint in chronic spontaneous urticaria, erasing millions in shareholder value in a single session. NEW YORK, July 7, 2026 /PRNewswire/ -- Evommune, Inc. (NYSE: EVMN) shareholders lost approximately 38% of their investment value on June 29, 2026, when the Company disclosed that its lead drug candidate EVO756 failed to meet the primary endpoint -- mean change in UAS7 at 12 weeks -- in its Phase 2b trial for moderate-to-severe chronic…

Article excerpt provided by the FMP news feed. AI is used only for the optional "Why this matters" read.Read full article ↗
seekingalpha.com1 Jul 2026

Evommune's Healthy Balance Sheet Buys Them Time For AD

Evommune, Inc.'s recent miss with EVO756's CSU indications is a major setback. I agree that this creates doubts about the rest of EVMN's pipeline because the same biology now needs cleaner data in AD and migraine. However, remember that EVO301 still gives EVMN another catalyst after their positive Phase 2a AD data.

Article excerpt provided by the FMP news feed. AI is used only for the optional "Why this matters" read.Read full article ↗
prnewswire.com30 Jun 2026

Evommune, Inc. Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Evommune, Inc. (EVMN)

Evommune's CEO and CSO sold shares on June 22, 2026, under Rule 10b5-1 plans adopted months earlier -- days before the Company disclosed that EVO756 failed its Phase 2b primary endpoint. NEW YORK, June 30, 2026 /PRNewswire/ -- Evommune, Inc. (NYSE: EVMN) shares dropped approximately 38% after the Company announced that its lead drug candidate EVO756 failed to meet the primary endpoint in a Phase 2b trial evaluating the treatment in adults with moderate-to-severe chronic spontaneous urticaria.

Article excerpt provided by the FMP news feed. AI is used only for the optional "Why this matters" read.Read full article ↗
Older updates drop into a lighter feed
businesswire.com
29 Jun 2026
Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Chronic Spontaneous Urticaria
Read ↗
businesswire.com
7 May 2026
Evommune Reports First Quarter 2026 Financial Results and Provides Business Highlights
Read ↗
Earnings news

EVMN earnings headlines

This section is separated from the general news feed so investors can quickly connect the latest headlines with the structured earnings report.

1
businesswire.com29 Jun 2026

Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Chronic Spontaneous Urticaria

PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) (the “Company” or “Evommune”), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced top-line results from its randomized, double-blind, placebo controlled, dose-ranging Phase 2b trial evaluating the efficacy and safety of oral MRGPRX2 antagonist, EVO756, in adults with moderate-to-severe chronic spontaneous urticaria (CSU).The Phas.

2
businesswire.com7 May 2026

Evommune Reports First Quarter 2026 Financial Results and Provides Business Highlights

PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) (“Evommune” or the “Company”), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced financial results for the first quarter ended March 31, 2026, and provided a business update. “We continue to make meaningful progress across our broad chronic inflammation targeted pipeline and remain on track to deliver top-line Phase 2b data for.

Beyond the headline

A deeper look for beginners

Generate a short AI read that goes beyond the headlines above, plus a plain-English breakdown of what it could mean going forward.

Continue your EVMN research
Use the stock analysis page for a fuller technical read, open TradingView for charting, or head to Platforms when you are ready to place a trade.
Stock AnalysisOPEN ON TRADINGVIEW ↗TRADE THIS STOCK